Allied Market Research: Global Neurobiomarkers Market for Alzheimer's and Parkinson's Diseases to Reach $8.57 Billion by 2025

Recently, VCBeat (WeChat Official Account: vcbeat) learned from foreign media reports that Allied Market Research has published a report titled “Alzheimer’s and Parkinson’s Disease Neurological Biomarkers Market - Global Opportunity Analysis and Industry Forecast, 2018-2025.” The report indicates that the global market for neurological biomarkers in Alzheimer’s and Parkinson’s diseases was valued at $3.95 billion in 2017 and is projected to reach $8.57 billion by 2025, representing a compound annual growth rate (CAGR) of 10.1% from 2018 to 2025. VCBeat (WeChat Official Account: vcbeat) has compiled the key highlights of this report for you:

The development of cost-effective biomarker testing methods, the growing demand for non-invasive diagnostic technologies, and the increasing adoption of biomarkers in clinical trials are driving market growth. However, stringent government regulations and ethical concerns related to early diagnosis are restraining market expansion. On the other hand, the rising demand for personalized medicine will create new opportunities for the biomarker market.

Image source: Unsplash official website

Driven by a significant increase in the number of educational institutions and heightened R&D activities, the U.S. Alzheimer’s disease biomarkers market accounted for more than one-third of global revenue in 2017. Due to the growing population of individuals with Alzheimer’s disease in countries such as India and Japan, the Asia-Pacific dementia biomarkers market is projected to grow at a compound annual growth rate (CAGR) of up to 12.7% from 2018 to 2025.

Driven by the growing number of Parkinson’s disease patients and the increasing uptake of pharmacological therapies and surgical interventions, China’s Parkinson’s disease biomarker market is projected to expand at a compound annual growth rate (CAGR) of up to 10.1% from 2018 to 2025. However, owing to the rising prevalence of Parkinson’s disease among the elderly population in the United States, the U.S. accounted for more than one-third of the global Parkinson’s disease biomarker market share in 2017.

The key market players analyzed in the report include Abbott Laboratories, Proteome Sciences, Myriad RBM, Athena Diagnostics, Thermo Fisher Scientific, Quanterix Corporation, Immunarray Pvt. Ltd, Psynova Neurotech, Diagenic ASA, and Bio-Rad Laboratories. These market participants have adopted strategies such as partnerships, collaborations, expansions, and joint ventures to consolidate their positions in this industry.

Allied Market Research (AMR) is a full-service market research and business consulting firm based in Portland, Oregon. AMR provides exceptional “Market Research Reports” and “Business Intelligence Solutions” to global enterprises as well as small and medium-sized businesses. AMR delivers targeted business insights and advisory services to help its clients make strategic decisions and achieve sustainable growth in their respective markets.